// App-Quantinova.ai

3511.0 : CodeBreak 100: Phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).

Researchers

Presenter

  • David S. Hong

Principal Investigators

  • James Kuo

  • Adrian G. Sacher

  • Fabrice Barlesi

  • Benjamin Besse

  • Yasutoshi Kuboki

  • Grace K. Dy

  • Vikas Dembla

  • John C. Krauss

  • Timothy F. Burns

  • June Kim

  • Haby Henary

  • Gataree Ngarmchamnanrith

  • Bob T. Li

Medical Centers

  • 1.MD Anderson Cancer Center, Houston, TX

  • Scientia Clinical Research, Sydney, Australia

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Aix Marseille University, Marseille, France

  • Gustave Roussy Cancer Campus, Villejuif, France

  • National Cancer Center, EPOC, Chiba, Japan

  • Roswell Park Comprehensive Cancer Center, Buffalo, NY

  • Gibbs Cancer Center, Greer, SC

  • University of Michigan, Ann Arbor, MI

  • University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, PA

  • Amgen Inc, Thousand Oaks, CA

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • United States

  • Australia

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Dose Escalation

Phase

  • NA

Study Id's

  • NCT03600883

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved